Torbay Hospital Leads UK in Advanced Prostate Cancer Trial Recruitment

Pioneering international study evaluates new targeted drug, offering hope for patients with advanced prostate cancer.

Generic image of a medical research vial with a blue liquid.
AI

Generic image of a medical research vial with a blue liquid.

Torbay Hospital has become the first in the UK to recruit a patient for an international trial investigating a new targeted drug, ifinatamab deruxtecan (MK-2400), for advanced prostate cancer.

Four patients at Torbay and South Devon NHS Foundation Trust are participating in the pioneering MK2400-001 study. The trial aims to assess if the targeted drug can serve as an alternative to standard chemotherapy for patients whose cancer has spread and continues to grow despite hormone treatment.
Researchers will evaluate the treatment's potential to extend patients' lives, slow disease progression, and potentially reduce chemotherapy-related side effects. Unlike traditional chemotherapy, which affects both cancerous and healthy cells, MK-2400 is designed to target a specific protein found on prostate cancer cells, delivering medication directly into tumour cells and minimising damage to healthy tissue.
“

"I was first diagnosed in 2018 and it was Dr Lydon who told me about the trial earlier this year. When I was asked if I’d like to be involved, I didn’t let Dr Lydon finish the sentence – I said yes immediately! I started treatment in July and was both excited and anxious, but the team has been so supportive. When I think about my previous treatment and how unwell it made me feel because it attacks everything, I’m hoping this new targeted treatment will have fewer side effects. If everything goes well, I can continue having the treatment indefinitely, which is much longer than the usual standard of care drug. It feels like a positive experience has come out of a negative situation and I’m just grateful for the opportunity."

Dominic Gover · Trial Patient
Dr Anna Lydon, Clinical Oncologist at Torbay and South Devon NHS Foundation Trust and the trial’s Principal Investigator, expressed optimism about the treatment's potential. "We are always trying to offer patients treatments that don’t upset their daily living unduly and this trial drug offers the real hope of that," she stated. "We are so pleased to have this trial available to our patients in Torbay and South Devon and are very grateful to those men who are taking part."
The trial, which closes to recruitment in August 2027, is evaluating the targeted approach for its potential to improve outcomes and quality of life for patients with advanced prostate cancer.
Based on information from the official source: Torbay and South Devon NHS Foundation Trust (18/11/2026)